Last reviewed · How we verify
new antiviral therapy — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
new antiviral therapy (new antiviral therapy) — Assistance Publique - Hôpitaux de Paris.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| new antiviral therapy TARGET | new antiviral therapy | Assistance Publique - Hôpitaux de Paris | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- new antiviral therapy CI watch — RSS
- new antiviral therapy CI watch — Atom
- new antiviral therapy CI watch — JSON
- new antiviral therapy alone — RSS
Cite this brief
Drug Landscape (2026). new antiviral therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/new-antiviral-therapy. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab